Muzzey Dale

Muzzey Dale, Chief Scientific Officer at Myriad Genetics (MYGN), has demonstrated a consistent pattern of selling company stock over the past several years, with no recorded purchases in SEC filings. Since 2024, Dale has executed 24 transactions—all sales—totaling $561,325.70 in value, with the most recent activity occurring in March 2026. The sales have been structured in multiple tranches, often clustered around mid-to-late March, suggesting a possible adherence to predetermined trading plans. For example, between March 12 and March 22, 2026, Dale sold shares worth $92,470.02 across five transactions, including a $55,682.34 sale on March 15. Similar patterns appear in prior years, with notable sales in March 2025 ($160,525.01 across four filings) and March 2024 ($130,312.04 across five filings). The transactions, coded as "F" for discretionary sales, indicate an ongoing divestment strategy rather than sporadic disposals. Smaller sales, such as the $2,570.70 transaction on January 1, 2026, and $5,717.07 on January 1, 2025, suggest partial liquidations alongside larger dispositions. The absence of any buy transactions reinforces a one-directional trend, though the filings do not specify whether the sales represent full exits or partial reductions in holdings. Dale’s activity remains exclusively tied to MYGN, with no diversification into other securities evident in the data. The regularity of March transactions could align with vesting schedules or tax planning, but the filings provide no explicit rationale beyond the disclosed sales.